The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Anbio Biotechnology, a leader in in-vitro diagnostic technologies, announced its participation in three international exhibitions in May 2025: EuroMedLab in Brussels, AVA Conference in Sydney, and ...

NNNN is currently pivoting from pandemic tests and expanding its assays into oncology, cardiovascular, hormonal, and infectious diseases. Their 2024 revenues increased YoY with gross margin improving ...

Anbio Biotechnology (NNNN) has filed to raise $8.8 million in an IPO of its Class A ordinary shares, according to an SEC F-1 registration statement. NNNN provides in vitro diagnostics products for ...

Anbio Biotechnology NNNN reported full-year 2025 results on Tuesday, with sales rising to $8.65 million from $8.19 million in 2024. Net income surged to $6.4 million, up from $2.37 million, while ...

FRANKFURT, Germany, Aug. 08, 2025 (GLOBE NEWSWIRE) -- In response to recent outbreaks of Chikungunya fever, Anbio Biotechnology has announced the launch of its Chikungunya IgM/IgG Rapid Test, offering ...

FRANKFURT AM MAIN, Germany, March 17, 2026 (GLOBE NEWSWIRE) -- Anbio Biotechnology (NASDAQ: NNNN) ("Anbio" or the "Company"), a global diagnostic company in in-vitro diagnostic (IVD) technologies, ...

BRUSSELS, May 15, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology, a global leader in in-vitro diagnostic (IVD) technologies, is pleased to announce its participation in three major international ...

Investing.com -- Anbio Biotechnology, a global diagnostic company, announced the pricing of its initial public offering (IPO) at $5.00 per Class A Ordinary Share. However, the shares opened at a ...

Anbio Biotechnology (NNNN) is down -26.6%, or -$9.30 to $25.62. Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you ...

Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide. FRANKFURT, Germany, Aug. 8, 2025 ...